Macular diseases, particularly those age-related, are among the leading causes of vision loss in adults. Early identification of degenerative changes and effective monitoring of disease progression rely heavily on advanced imaging technologies. Spectral optical coherence tomography (SOCT), OCT angiography (OCT-A), and algorithm-driven retinal analysis together form a new diagnostic standard—an evolution described as “Diagnostics 2.0.” The article focuses on modern diagnostic tools that integrate advanced imaging with data analysis for the evaluation of macular diseases, and it features Optopol products. It also offers guidance on selecting devices that may best suit the needs of your ophthalmology practice.
SOCT + funduscamera = REVO FC 130
The REVO FC 130 optical tomograph introduces a new generation of diagnostic technology. It is a comprehensive imaging platform that combines standard OCT of the posterior and anterior segments of the eye with a color fundus camera, and offers optional modules such as OCT angiography, corneal topography, and B-OCT biometry. Using automated protocols and AccuTrack™ eye-tracking, the system allows you to evaluate the macula from different angles in a single examination, without the need to spend extra time positioning the patient. The REVO FC optical tomograph enables simultaneous and synchronized imaging by capturing a color fundus photograph and automatically linking it to the corresponding OCT scans. Features such as Auto Fundus Registration and the ability to link a single fundus image to multiple OCT examinations support precise identification of macular changes and enable reliable evaluation of disease progression over time.
AI: massive support in detecting changes
The latest REVO FC 130 model is equipped with an AI module that supports retinal layer segmentation, a critical feature for the detection of conditions such as dry and wet AMD. By leveraging AI-powered algorithms, this device automatically and accurately recognizes retinal layers, significantly reducing analysis time and improving the accuracy of treatment outcome evaluations.
Non-contrast angiography: a safe and repeatable technique
Previously offered as an optional module, OCT-A is now rapidly gaining ground. Alongside standard OCT, the REVO FC provides retinal angiography that enables visualization of blood vessels without the need to administer dye. It is a safe, accurate, and non-invasive tool for the assessment of macular microcirculation, detection of lesions, and evaluation of the patient’s response to therapy.
Ultra-high resolution and incredible speed – the REVO HR
With a scanning speed of 130,000 A-scans per second and a resolution of up to 3 µm, the REVO HR SOCT is a compelling option for specialist centers. Its superior imaging quality makes it easier to see even microscopic macular changes such as subtle pigment mottling or minor focal hyperfluorescence. Combined with the AI Retina add-on and the OCT-A module, the device serves as a comprehensive diagnostic solution for modern ophthalmic clinics.
Comprehensive reports and progression analysis
The REVO platform provides easy access to complete OCT and OCT-A data, as well as correlated photos, through a user-friendly interface. Features such as Structure + Function and progression reports facilitate straightforward comparison of macular changes over time. This is vital for monitoring anti-VEGF therapy in AMD, analyzing SRF volume, or assessing retinal thickness. The data can be exported to EMR or DICOM, which allows you to compare results between visits and share them with external specialists.
Benefits for patients and doctors
Early and accurate diagnosis allows subtle macular changes to be identified at an earlier stage without the need for contrast injection. Treatment monitoring becomes easier, as disease progression or regression after therapy can be assessed through direct comparison of examinations stored within a single system. Safety and comfort are improved because OCT-A eliminates the need for a dye injection, enabling more frequent examinations without the risk of adverse reactions. Improved patient education is supported by colorful fundus images, progression charts, and clearly presented data that help patients better understand the course of their disease.
In a nutshell
Retinal Diagnostics 2.0 is more than just a new stage in imaging technology. It marks a shift in the approach to the management of macular diseases. With devices such as the REVO FC 130 and REVO HR, clinicians can obtain a rapid, comprehensive, and integrated view of the condition of the retina without the need to perform several separate tests. For patients, this means a safer, faster, and more comfortable examination, while practices benefit from greater diagnostic precision, higher work efficiency, and a competitive advantage. Discover how the REVO series devices can elevate your daily practice. Contact one of our representatives or schedule a demonstration of the model that interests you.